Pharmacogenomics: Into the new millennium

Drug Development Research

Volumn 49, Issue 1, 2000, Pages 17-21

  Kadens, Darien T ^a   Le Gear, Michele L ^b  

^a Mitsui & Co Ltd   (Japan)

^b Migenix Inc   (United States)

Author keywords

Genomics; Pharmacogenetics; Pharmacogenomics

Indexed keywords

DRUG;

ARTICLE; BIOTECHNOLOGY; COST CONTROL; DRUG RESEARCH; GENE TECHNOLOGY; HEALTH CARE INDUSTRY; HEALTH CARE SYSTEM; HEALTH MAINTENANCE ORGANIZATION; PHARMACEUTICS; PHARMACOGENETICS; PHARMACOGENOMICS; PRIVACY; RISK MANAGEMENT;

EID: 0034100996     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2299(200001)49:1<17::AID-DDR3>3.0.CO;2-Y     Document Type: Article

References (5)

1. Carey CT. 1998. Why pharmaceutical companies and MCO's should share risk. Drug Benefit Trends 10:35-40, 42, 44.
2. Marshall A. 1997. Getting the right drug into the right patient. Nat Biotechnol 15:1249-1252.
3. PhRMA. 1998. PhRMA facts and figures, March.
4. PhRMA. 1999. PhRMA Annual Survey.
5. Vargas E, Puerro M, Moreno A, Simon J, Martin JC, Gonzalez-Callejo MA, Jaime M, Gomez-Mayoral B, Duque F, Gomez-Delgado A. 1998. Effect of adverse drug reactions on length of stay in intensive care units. Clin Drug Invest 15:353-360.